Clinical trials
IgG4-Related Diseases clinical trials
Below are recruiting igg4-related diseases clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07190196RecruitingPhase 3
Study of Rilzabrutinib for IgG4-related disease
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
Fontana, CaliforniaAges 18 years+ - NCT03023371Recruiting
National registry for IgG4-related disease in China
This study is a registry that collects information about people diagnosed with IgG4-related disease (a specific immune-related condition). It helps doctors better understand the condition and how it looks and behaves in real life.
Beijing, Beijing MunicipalityAges Any age - NCT03473912Recruiting
Rheumatoid disease biobank study for adults
This study asks adults with a rheumatoid condition to join a biobank, which is a safe place to store health information and biological samples for future research. It may help researchers better understand rheumatoid conditions and develop better treatments.
Kfar SabaAges 18–120 - NCT06285539RecruitingPhase 2
Testing a drug for rare inflammatory diseases
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
AmsterdamAges 18–65 - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06663618Recruiting
Steroid and mycophenolate for IgG4-related disease
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
Beijing, Beijing MunicipalityAges 18–80 - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+ - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07061938RecruitingPhase 1/Phase 2
Study of ACE1831 for active IgG4-related disease
This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.
Atlanta, GeorgiaAges 18–75 - NCT07068165RecruitingPhase 2/Phase 3
Lenalidomide for active IgG4-related disease
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
BeijingAges 18–75 - NCT07104058Recruiting
FAPI PET scan to predict relapse in IgG4-RD
This study tests whether a special PET scan (FAPI PET/CT) can detect tiny signs of disease activity (MRD) in people with stable IgG4-RD, and whether it helps predict who might relapse.
Beijing, Beijing MunicipalityAges 18–75 - NCT07148791RecruitingPhase 2
CAR-T therapy for relapsed or refractory IgG4-related disease
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT01670695Recruiting
Study people with IgG4-related disease in China
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
Beijing, Beijing MunicipalityAges 18–75 - NCT07536841Recruiting
Testing New Criteria for Autoimmune Pancreas Inflammation
This study validates a new diagnostic tool (Odesa Criteria 2026) to help doctors accurately identify autoimmune pancreatitis—a rare condition where the body attacks the pancreas. If you're being evaluated for possible pancreas inflammation, this trial may help confirm whether you have this specific type.
OdesaAges 18 years+ - NCT07339540RecruitingEarly Phase 1
BCMA gene therapy for recurring autoimmune diseases
This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.
Wuhan, HubeiAges 18–65 - NCT06777914Recruiting
Genes linked to rare liver disease and cancer risk
This study looks at whether certain family-related genes make people more likely to develop liver or bile duct cancers without a clear cause. If you had surgery or a transplant for one of these cancers and have had unexplained high liver enzymes or itching, this trial may help find genetic clues.
Bologna, BolognaAges 1 year+ - NCT05789030Recruiting
Treating IgG4-related disease with mild steroid starts
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
BeijingAges 18–75
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for igg4-related diseases?
- Yes. Clin2 currently lists 20 recruiting igg4-related diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a igg4-related diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a igg4-related diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.